APP and Alzheimer disease: APP Iberian was firstly described in an in vitro assay with a dramatically increased Aβ1-42/Aβ1-40 ratio which is mainly based on a strongly decreased Aβ1-40 production, as determined by radiolabeled immunoprecipitation followed by SDS PAGE analysis [28] and later also in different AD patients [29, 95, 96].